<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914900</url>
  </required_header>
  <id_info>
    <org_study_id>INT40/10</org_study_id>
    <nct_id>NCT01914900</nct_id>
  </id_info>
  <brief_title>Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer</brief_title>
  <official_title>Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of preoperative chemotherapy with docetaxel, cisplatin and&#xD;
      5-fluorouracil (TPF) in locally advanced resectable oral cavity squamous cell cancer. The aim&#xD;
      is to improve the rate of pathological complete response to induction chemotherapy in a&#xD;
      molecular enriched population, consisting of patients with tumour harbouring a functional p53&#xD;
      protein and/or showing low expression of beta-tubulin II.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete remission</measure>
    <time_frame>After 9 weeks since chemotherapy start</time_frame>
    <description>For what concerns primary endpoint of pathologic complete remission achievement, the patients will be assessed at time of surgery, i.e., after about 9 weeks since chemotherapy start.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Patients will be followed up to 5 years for what concerns PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Patients will be followed up to 5 years for what concerns OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to induction chemotherapy</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient receiving postoperative radiotherapy and chemotherapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early functional response evaluation by DWI and DCE MRI</measure>
    <time_frame>3 weeks</time_frame>
    <description>radiological evaluation after 1 cycle of induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between (DWI - DCE) MRI response and pathological response</measure>
    <time_frame>9 weeks</time_frame>
    <description>comparison between radiological assessment of response and pathological one</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Locally Advanced Resectable Oral Cavity Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>induction TPF chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cisplatin, 5 fluorouracil</intervention_name>
    <arm_group_label>induction TPF chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Males and females age &gt; 18 years&#xD;
&#xD;
          -  Histologically proved primary oral cavity squamous cell cancer (tumour extending to&#xD;
             oropharynx are accepted if oropharyngeal invasion is &lt; 20% of the tumour size)&#xD;
&#xD;
          -  Stage T2 (T2 stage is accepted if tumour size is 3 cm or larger).-T3, N1- N3 and T4a&#xD;
             any N&#xD;
&#xD;
          -  WHO performance status &lt; 1&#xD;
&#xD;
          -  Availability of block of Formalin Fixed Paraffin Embedded (FFPE) biopsy of the tumour&#xD;
&#xD;
          -  Radiological imaging of the tumour with MRI pre-therapy&#xD;
&#xD;
          -  Effective contraception for both male and female subjects if risk of conception exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior antitumour therapy for head &amp; neck cancer (chemotherapy or biological therapy&#xD;
             and radiotherapy)&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Medical condition that contraindicate administration of TPF scheme, in particular:&#xD;
&#xD;
               1. clinically significant cardiac disease including unstable angina, acute&#xD;
                  myocardial infarction in the previous 2 years, congestive heart failure and&#xD;
                  arrhythmia requiring therapy&#xD;
&#xD;
               2. chronic or current infectious disease that contraindicate administration of&#xD;
                  chemotherapy causing neutropenia; known HIV, Hepatitis B or C positivity&#xD;
&#xD;
               3. uncontrolled renal, hepatic, neurological, cerebral, psychiatric, haematological,&#xD;
                  gastrointestinal, pulmonary, vascular or endocrine diseases that could interfere&#xD;
                  with antiblastic treatment&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy according to Common Toxicity Criteria (CTC) Adverse&#xD;
             Event grade &gt; 1&#xD;
&#xD;
          -  Pre-existing ototoxicity grade &gt; 1&#xD;
&#xD;
          -  Previous diagnosis of other cancer in the last 3 years (in situ cervical cancer or&#xD;
             completely excised basocellular/squamocellular skin cancer are always admitted )&#xD;
&#xD;
          -  Previous other cancer in oral cavity to less than 2 cm from existing primary&#xD;
&#xD;
          -  Breast feeding women or women with a positive pregnancy test at Visit 0 or 1&#xD;
&#xD;
          -  Screening laboratory values:&#xD;
&#xD;
               -  Neutrophils &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelets &lt; 100 x 109/L&#xD;
&#xD;
               -  ALT or AST &gt; 2.5 times upper limit of normal&#xD;
&#xD;
               -  Calculated creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
               -  Weight loss more than 20% in 3 months preceding the study&#xD;
&#xD;
               -  Technical unresectability defined as: T4b staging or N ulcerating the skin or&#xD;
                  encasing internal carotid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Lisa Licitra</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>oral cavity cancer</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>TP53</keyword>
  <keyword>beta tubulin II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

